Abingdon Health plc, listed on London’s AIM market, has completed a secondary listing on the OTCQB Venture Market in the United States.

The firm is a developer, manufacturer and regulatory services provider for rapid diagnostic tests and MedTech.

The OTCQB is designed for entrepreneurial and development stage US and international companies. Foreign Private Issuers, such as Abingdon Health, that trade on the OTCQB are exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they make whatever information is required by their home market regulator publicly available to US investors in English.

Abingdon Health will therefore face no extra reporting obligations and incur minimal ongoing costs.